AccessibilityHelpAbout Us
PureTech Health Plc logo

PureTech Health Plc(LSE) PRTC

Market Cap£275.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-37%
5 Year-68%
1 Year-8%
1 Month-2%
£1.16
+3.39%
+0.04Today
PureTech Health Plc last closing stock price
MetricPriceDate
Last closeGBX 116.002026-09-23
PureTech Health Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.85%GBX 119.402026-09-16
1 month-2.36%GBX 118.802026-08-24
3 month-11.85%GBX 131.602026-06-25
Year to date-7.2%GBX 125.002025-12-31
1 year-7.5%GBX 125.402025-09-23
3 year-44.63%GBX 209.502023-09-22
5 year-67.6%GBX 358.002021-09-24
Since inception-36.97%GBX 1.782015-06-19

PureTech Health Plc Financials at a Glance

Market Cap

£275.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$12.19M

Net Income (TTM)

$51.15M

EPS (TTM)

-£0.00

P/E Ratio

255.00

Dividend

£0.00

Beta (Volatility)

0.00 (Low)

Price

£1.16

Volume

1,435,340

Open

£1.12

Previous Close

£1.16

Daily Range

£1.10 - £1.16

52-Week Range

£1.07 - £1.43

Estimated Earnings Date

Sep 22, 2026

PRTC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PureTech Health Plc

PureTech Health plc is a biotechnology company focused on developing differentiated medicines for serious diseases, including inflammatory, fibrotic, and immunological conditions. The company operates through various segments, including Internal, Controlled Founded Entities, and Non-Controlled Founded Entities, aiming to address unmet medical needs.

Products and Services
  • Innovative therapies for inflammatory and fibrotic diseases
  • Targeted treatments for intractable cancers
  • Advanced solutions for neurological and gastrointestinal disorders
Growth Outlook
  • Recent quarterly revenue increased to $2.82 million, showing growth potential
  • Cash and short-term investments totaled $278.99 million, providing financial stability
  • Strong market demand for innovative therapies supports future expansion
Financial Highlights
  • Trailing twelve months revenue of $4.02 million, indicating upward momentum
  • Net income for Q4 2025 reported at -$65.45 million, reflecting ongoing investment in R&D
  • Cash at the end of Q4 2025 was $254.16 million, ensuring operational liquidity
PureTech Health plc is positioned in the biotechnology sector, focusing on developing innovative treatments for complex diseases. The company's diverse product pipeline and strong financial backing provide a solid foundation for future growth. Recent financial results indicate a commitment to research and development, which is essential for long-term success in the competitive healthcare landscape. With a significant cash reserve, PureTech Health is well-equipped to navigate challenges and capitalize on emerging opportunities in the biotechnology field.
AI Generated • Sep 18, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Robert William Henry Lyne

Website

puretechhealth.com

Headquarters

Boston, MA 02210, US

PRTC Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

47.85%

Return on Capital

-30.30%

Return on Assets

N/A

Earnings Yield

0.39%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

£275.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

245.18M

Volume

1.44M

Avg. Volume

680.72K

Financials (TTM)

Gross Profit

$22.94M

Operating Income

-$219.73M

EBITDA

-$43.10M

Operating Cash Flow

-$181.73M

Capital Expenditure

-$17.04K

Free Cash Flow

-$181.75M

Cash & ST Invst.

$222.51M

Total Debt

$18.57M

PureTech Health Plc Performance Analysis

PureTech Health Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 12,679,2100.3%
20232023-12-31USD 2,678,891-78.9%
20242024-12-31USD 3,778,33341.0%
20252025-12-31USD 3,535,196-6.4%
PureTech Health Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-311298.3%
Q22025-06-30-54.0%
Q42025-12-3152.4%
Q22026-06-3023.6%
PureTech Health Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.14-6.5%
20232023-12-31USD -0.1933.2%
20242024-12-31USD 0.16N/A
20252025-12-31USD -0.35N/A
PureTech Health Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31333.3%
Q22025-06-30-154.3%
Q42025-12-31-42.1%
Q22026-06-30196.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$3.49M

+1110.7%

Gross Profit

$1.88M

+104.9%

Gross Margin

53.81%

N/A

Market Cap

£275.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£4.91M

N/A

Employees

56

N/A

Net Income

$65.92M

+257.8%

EBITDA

-$49.66M

+23.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$222.51M

-55.5%

Total Debt

$18.57M

-87.2%

Accounts Receivable

$8.57M

+317.0%

Inventory

$0.00

N/A

Long Term Debt

$9.21M

-93.1%

Short Term Debt

$9.36M

-13.7%

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$43.57M

+45.6%

Operating Cash Flow

-$43.57M

+45.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BXP.LBeximco Pharmaceuticals Limited
£0.63+0.00%
NIOX.LNIOX Group Plc
£0.68+0.90%
AGY.LAllergy Therapeutics plc
£0.05+0.00%
AVCT.LAvacta Group Plc
£0.75+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBDWarner Bros. Discovery
$30.76-0.23%
WHLRWheeler Real Estate Investment Trust
$5.44+190.91%
NVDANvidia
$225.51-1.47%
INTCIntel
$122.60-1.02%

Questions About PRTC

What is the current price of PureTech Health Plc?

PureTech Health Plc is trading at £1.16 per share.

What is the 52-week range for PureTech Health Plc?

Over the past 52 weeks, PureTech Health Plc has traded between £1.07 and £1.43.

How much debt does PureTech Health Plc have?

As of the most recent reporting period, PureTech Health Plc reported total debt of $14.69M.

How much cash does PureTech Health Plc have on hand?

PureTech Health Plc reported $188.89M in cash and cash equivalents in its most recent financial results.

What is PureTech Health Plc’s dividend yield?

PureTech Health Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services